Loading data for ENGN — first visit, this takes a few seconds.
enGene Therapeutics Inc. (ENGN)
NasdaqCM: ENGN
· Real-Time Price · USD
1.82
-0.01 (-0.55%)
At close: Sep 04, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
enGene Therapeutics Inc. (ENGN) Stock Price, Analysis & Data
No data available
| Bid | 1.82 |
| Market Cap | 122M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -127M |
| -0.27 | |
| -2.18 | |
| n/a | |
| -1.3 | |
| P/B (ttm) | 0.48 |
| P/S (ttm) | 0.00 |
| Earnings Date | Sep 14, 2026 |
| Ask | 2.3 |
| Volume | 412,684 |
| Avg. Volume (20D) | 870,901 |
| Open | 1.82 |
| Previous Close | 1.83 |
| Day's Range | 1.78 - 1.83 |
| 52-Week Range | 1.40 - 12.25 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ENGN
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings In...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 1, 2022
Employees 81
Stock Exchange NasdaqCM
Ticker Symbol ENGN
Website https://www.engene.com
Financial Performance
In 2025, enGene Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -117.3M, an increase of 112.73%.
Financial StatementsEarnings Surprise
enGene Therapeutics has released their quarterly earnings on Jun 15, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.43 exceeds estimates by 0.04, with 15.69% YoY growth.
enGene Therapeutics Inc. is scheduled to release its earnings on Sep 14, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2